Form 4: Cassava Sciences CFO Eric Schoen Reports Stock Option Grant

Eric Schoen, CFO of Cassava Sciences, reports the acquisition of 100,000 stock options.

Summary

• On September 6, 2024, Eric Schoen, the Chief Financial Officer of Cassava Sciences Inc., reported a transaction involving derivative securities.
• Schoen acquired 100,000 stock options with an exercise price of $26.91.
• These options vest over two years, with 50% vesting one year after the grant date and the remaining 50% vesting two years after the grant date.
• The options expire on September 6, 2034.
• Following the reported transaction, Schoen directly owns 100,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of 50% after one year and 50% after two years is fairly standard, encouraging long-term commitment.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the CFO's interests with the company's long-term success.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates